The estimated Net Worth of Philip Hodges is at least 206 千$ dollars as of 1 March 2021. Mr. Hodges owns over 6,000 units of Altimmune Inc stock worth over 62,601$ and over the last 6 years he sold ALT stock worth over 143,105$. In addition, he makes 0$ as Independent Director at Altimmune Inc.
Philip has made over 3 trades of the Altimmune Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 6,000 units of ALT stock worth 96,480$ on 1 March 2021.
The largest trade he's ever made was exercising 16,850 units of Altimmune Inc stock on 24 September 2020 worth over 120,815$. On average, Philip trades about 2,953 units every 18 days since 2019. As of 1 March 2021 he still owns at least 8,731 units of Altimmune Inc stock.
You can see the complete history of Mr. Hodges stock trades at the bottom of the page.
Philip L. Hodges serves as Independent Director of the Company. Mr. Hodges is Managing Partner of Redmont Capital, a private equity firm located in Birmingham, Alabama, which he joined at its inception in 1997. Redmont Capital is a co-founder of Altimmune. Mr. Hodges’ investment strategy is focused on high-growth small businesses within the health care, life science and technology sectors. He currently serves as a director for several of the firm’s portfolio companies. Mr. Hodges holds a Bachelor of Science in Business Administration from the Brock School of Business at Samford University. Mr. Hodges brings significant experience as a life science investor and co-founder to Altimmune’s board of directors.
Philip Hodges is 51, he's been the Independent Director of Altimmune Inc since 2017. There are 13 older and 1 younger executives at Altimmune Inc. The oldest executive at Altimmune Inc is David Drutz, 81, who is the Independent Director.
Philip's mailing address filed with the SEC is C/O ALTIMMUNE, INC.,, 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG, MD, 20878.
Over the last 7 years, insiders at Altimmune Inc have traded over 2,557,810$ worth of Altimmune Inc stock and bought 3,362,060 units worth 23,898,779$ . The most active insiders traders include Bioventures Ltd Novartis Ag...、Healthcare Capital Partners...、Mitchel Sayare. On average, Altimmune Inc executives and independent directors trade stock every 35 days with the average trade being worth of 432,889$. The most recent stock trade was executed by David Drutz on 19 August 2024, trading 41,750 units of ALT stock currently worth 106,463$.
altimmune, inc. is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. by leveraging specific attributes of its two independent and complementary platform technologies, altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. our densigen™ t-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual’s immune system against multiple target antigens instead of just one. altimmune’s respirvec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. vaxin’s product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current
Altimmune Inc executives and other stock owners filed with the SEC include: